Skip to main content

Autolus Therapeutics plc

AUTL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001730463

In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.

13F holders, Q4 2023

Institutional positions in Autolus Therapeutics plc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
99
+29 vs. Q3 2023
Shares held
115.9M
+5.20M (+4.7%) vs. Q3 2023
Total value
$746.6M
+$488.6M (+189.4%) vs. Q3 2023
New holders
34
20 more added
Sold out
5
20 more reduced

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2023: 99 institutions
Q1 2021: 63 institutionsQ2 2021: 69 institutionsQ3 2021: 59 institutionsQ4 2021: 73 institutionsQ1 2022: 66 institutionsQ2 2022: 67 institutionsQ3 2022: 66 institutionsQ4 2022: 71 institutionsQ1 2023: 65 institutionsQ2 2023: 69 institutionsQ3 2023: 71 institutionsQ4 2023: 99 institutionsQ1 2024: 120 institutionsQ2 2024: 111 institutionsQ3 2024: 101 institutionsQ4 2024: 110 institutionsQ1 2025: 95 institutionsQ2 2025: 94 institutionsQ3 2025: 96 institutionsQ4 2025: 89 institutionsQ1 2026: 84 institutionsQ2 2026: 83 institutions
Value heldQ4 2023: $746.6M
Q1 2021: $129.4MQ2 2021: $169.6MQ3 2021: $164.2MQ4 2021: $272.3MQ1 2022: $228.6MQ2 2022: $143.9MQ3 2022: $105.7MQ4 2022: $204.2MQ1 2023: $195.1MQ2 2023: $260.4MQ3 2023: $258.1MQ4 2023: $746.6MQ1 2024: $1.12BQ2 2024: $620.0MQ3 2024: $648.5MQ4 2024: $395.4MQ1 2025: $261.0MQ2 2025: $378.6MQ3 2025: $235.7MQ4 2025: $277.1MQ1 2026: $184.4MQ2 2026: $212.0M
Institutions holding AUTL and their total value by quarter
QuarterHoldersValue
Q2 202683$212.0M
Q1 202684$184.4M
Q4 202589$277.1M
Q3 202596$235.7M
Q2 202594$378.6M
Q1 202595$261.0M
Q4 2024110$395.4M
Q3 2024101$648.5M
Q2 2024111$620.0M
Q1 2024120$1.12B
Q4 202399$746.6M
Q3 202371$258.1M
Q2 202369$260.4M
Q1 202365$195.1M
Q4 202271$204.2M
Q3 202266$105.7M
Q2 202267$143.9M
Q1 202266$228.6M
Q4 202173$272.3M
Q3 202159$164.2M
Q2 202169$169.6M
Q1 202163$129.4M

Institutions, Q4 2023

Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q3 2023.

Institutions holding AUTL in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
National Asset Management, Inc.0$00.00%−17,000−100.0%Sold out
Virtu Financial LLC0$00.00%−13,880−100.0%Sold out
Focused Wealth Management, Inc0$00.00%−5,000−100.0%Sold out
Ulland Investment Advisors, LLC0$00.00%−1,000−100.0%Sold out
Innovis Asset Management LLC––––Not filed